A formulation of insulin—Exubera—that was marketed in the US in 2006–2007, but withdrawn by Pfizer because of its high price and dosing imprecision; other drug companies are developing inhalable insulins
For instance, in February 2015, Sanofi and Mankind Corporation (U.S.) collaborated to launch Afrezza (insulin human) Inhalation Powder, inhalable insulin. This launch enabled the company to strengthen its product portfolio in nasal drug delivery.
He shows managers and leaders tools to create a strategy to build and shape innovation ecosystems and illustrates those that failed and succeeded, such as Nokia's 3G handset that failed to profit because partners in its ecosystem did not complete their innovations in time; Pfizer's inhalable insulin, which failed when endocrinologists wouldn't allow the requirement of lung function testing; Michelin's tires designed to run for 125 miles after a blowout, impacted by a failure in understanding the way in which service centers would adopt the solution; and successes like Amazon, Hasbro, and Apple.
(New York, NY) said that the United States District Court for the Southern District of New York has denied a motion for a preliminary injunction that would have blocked further sales of its inhalable insulin medication, Exubera, in the United States.